Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Allogeneic bone marrow transplant (related donor)
What an allogeneic bone marrow transplant from a related donor is, how the conditioning regimen and stem cell infusion work, what the evidence says about engraftment and survival, who is a suitable candidate, approximate costs in Turkey against the UK, US and Germany, what recovery looks like week by week, the main risks including graft-versus-host disease, and how to choose a transplant centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Allogeneic Bone Marrow Transplant (Related Donor)
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
How does the transplant work? The conditioning regimen and infusion
The process follows four distinct phases. First, the donor undergoes evaluation: blood tests confirm HLA compatibility, and a matched sibling typically shares one HLA haplotype from each parent, giving up to a full 10 of 10 or 12 of 12 allele match. Next, the patient enters a conditioning regimen — high-dose chemotherapy, sometimes combined with total body irradiation — lasting four to seven days. This destroys remaining diseased marrow cells and suppresses the immune system enough to prevent rejection of the donor cells.
Stem cells are then collected from the donor, either directly from the hip-bone marrow under general anaesthesia (the classic bone marrow harvest), or from peripheral blood after the donor is given granulocyte colony-stimulating factor (G-CSF) injections for four to five days to mobilise stem cells into the bloodstream (peripheral blood stem cell collection, or PBSC). The collected cells are infused into the patient through a central venous line — a process that looks like a blood transfusion and takes one to several hours. Finally, engraftment begins: over approximately two to four weeks the donor cells migrate to the marrow, multiply and begin producing new blood cells. Doctors monitor blood counts daily until engraftment is confirmed.
What does the evidence say about survival and engraftment?
Outcomes depend heavily on the underlying disease, its stage at transplant, the patient's age and fitness, and the degree of HLA matching. For many blood cancers — including acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome and aplastic anaemia — a matched related donor transplant is the recognised standard of care when a sibling match is available. Professional bodies including the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Transplantation and Cellular Therapy (ASTCT) publish disease-specific guidelines on when transplant is indicated and when alternatives such as chemotherapy alone or autologous transplant are preferred.
A matched sibling donor generally produces engraftment rates above 95 % and carries a lower incidence of severe graft-versus-host disease (GvHD) than a matched unrelated donor. Long-term survival figures vary widely by disease and stage: for AML in first complete remission, five-year overall survival after a matched related donor transplant is in the range of 50–70 % in published registry studies; for severe aplastic anaemia in younger patients it exceeds 80 % in many series. These are population figures, not individual predictions. No centre can guarantee an outcome, and any that does should be treated with caution.
Who is a good candidate, and who is not?
A transplant team considers several factors before recommending this procedure:
- Disease indication: the condition must be one for which transplant is known to offer meaningful benefit — typically blood cancers, bone marrow failure syndromes or certain genetic blood disorders.
- Disease status: transplant performed in remission or low disease burden generally produces better outcomes than transplant in relapse.
- Donor availability: a related donor who is HLA-compatible and medically fit to donate is the starting point; without one, an unrelated or haploidentical donor programme is considered instead.
- Patient fitness: age alone is not a cut-off, but heart, lung, kidney and liver function must be adequate; reduced-intensity conditioning (RIC) has extended eligibility to older or less fit patients.
- Informed willingness: the patient must understand the duration, risks and need for prolonged follow-up and immunosuppression.
Transplant is not appropriate if the disease is not controlled enough to justify the procedure risk, if no compatible donor is available, or if organ function makes conditioning too dangerous. The haematologist and transplant physician make this decision jointly, usually after a multidisciplinary team meeting.
Allogeneic bone marrow transplant cost in Turkey compared with the UK, US and Germany
Bone marrow transplantation is one of the most resource-intensive procedures in medicine. Quoted prices typically cover conditioning chemotherapy, the transplant itself and the in-patient stay through early engraftment, but packages vary; ask for a written line-by-line breakdown. The figures below are approximate ranges; each hospital confirms its own price.
| Country | Approximate cost range |
|---|---|
| Turkey | €40,000 – €90,000 |
| United Kingdom | €120,000 – €200,000 |
| United States | €200,000 – €400,000 |
| Germany | €100,000 – €180,000 |
What changes the price: the conditioning regimen intensity (myeloablative versus reduced-intensity), the length of in-patient stay (typically four to eight weeks for the core programme), the complexity of GvHD management, the need for intensive-care support, prophylactic antifungal and antiviral drugs, and the number of follow-up outpatient visits included. A package should normally cover pre-transplant HLA typing and fitness workup, conditioning chemotherapy, the infusion procedure, in-patient nursing through engraftment, isolation room, and standard supportive medications; clarify whether donor evaluation and collection costs are included. Find out how the centre prices extended stays if engraftment is delayed or complications arise. Learn more about how our process works before requesting a quote.
What does the procedure feel like, and how long is the hospital stay?
Patients describe conditioning as the most difficult phase: high-dose chemotherapy typically causes nausea, mucositis (soreness of the mouth and gut), fatigue and hair loss. Supportive care — anti-emetics, mouth-care protocols, fluids and nutrition — reduces but does not eliminate discomfort. The infusion day itself (often called "Day 0") is usually less dramatic; patients describe it as a long, quiet transfusion with close nursing observation for infusion reactions.
The two to four weeks after infusion are the most medically fragile. Blood counts fall to their lowest — the nadir — and the patient is vulnerable to serious infections and bleeding. Isolation precautions, prophylactic antibiotics, antifungals and antivirals, and daily blood-count checks are standard. Once counts recover consistently, discharge to outpatient follow-up becomes possible. Total in-patient time is commonly four to eight weeks for an uncomplicated course; complications extend this significantly. Plan for a companion or family member to be with you throughout.
Recovery milestones after discharge
The first three months after transplant are the period of greatest risk. Patients remain on immunosuppressive drugs (usually tacrolimus or ciclosporin, often with methotrexate or mycophenolate) to prevent GvHD. Weekly outpatient blood tests are standard. Energy returns slowly; most people cannot work for three to six months. Vaccinations that were wiped out by conditioning must be repeated from about six months post-transplant according to a schedule agreed with the team.
By one year, many patients are off immunosuppression if GvHD has been controlled, and most have returned to normal activity, though fatigue can persist. The immune system takes one to two years to fully reconstitute. If you are travelling to Turkey for transplant, your team will need to arrange follow-up with a haematologist in your home country, as most of the critical period — including GvHD monitoring, infection management and drug adjustment — takes place after you return home. Confirm this continuity plan in writing before you proceed. Learn more about how the process is coordinated.
Risks: graft-versus-host disease and other serious complications
The principal risk specific to allogeneic transplant is graft-versus-host disease, in which the donor immune cells recognise the patient's tissues as foreign and attack them. Acute GvHD typically appears in the first three months and can affect the skin, gut and liver; chronic GvHD appears later and can affect almost any organ. The EBMT and ASTCT report that moderate to severe chronic GvHD occurs in roughly 20–50 % of matched related donor transplants depending on donor and patient age and conditioning type. Immunosuppressive treatment manages most cases, but severe GvHD can be life-threatening and is the leading non-relapse cause of death after transplant.
Other serious risks include:
- Serious infection during the period of immune suppression — bacterial, fungal and viral (particularly cytomegalovirus reactivation).
- Graft failure — the donor cells fail to engraft or are rejected; a second transplant may be attempted.
- Organ toxicity from conditioning — liver (veno-occlusive disease / sinusoidal obstruction syndrome), lungs and kidneys can be damaged.
- Relapse of the original disease, which is distinct from transplant-related mortality.
- Late effects — infertility, cataracts, secondary cancers and endocrine problems occur in a minority of long-term survivors.
These risks are well-documented by the NHS, EBMT, ASTCT and the Blood and Marrow Transplant Clinical Trials Network. Ask the centre for its own centre-specific outcomes data, which accredited centres are obliged to record and submit to national or international registries.
How to choose a transplant centre and red flags
Bone marrow transplant is a highly specialised procedure. Accreditation by JACIE (the Joint Accreditation Committee of ISCT and EBMT) is the European standard for transplant programme quality; ask whether the centre holds JACIE accreditation. Beyond accreditation, consider:
- The centre's annual transplant volume — experienced programmes generally have better-developed protocols and complication management.
- Whether the centre publishes its outcomes to a national or international registry (EBMT registry data is publicly searchable by country).
- A named haematologist and transplant physician who will manage you throughout, with clear contact details.
- A written protocol covering conditioning regimen, GvHD prophylaxis, infection prophylaxis and the discharge criteria.
- A confirmed plan for follow-up with a haematologist in your home country, including who receives and acts on results.
Red flags include centres that cannot name their JACIE accreditation status, that do not submit to any outcomes registry, that quote a fixed programme price without itemisation, that pressure you to decide quickly, or that make statements about guaranteed remission or cure. Use our free quote page to request a written plan from a verified centre.
Questions to ask the transplant centre before you decide
- Is the programme JACIE-accredited, and can you provide the certificate?
- How many allogeneic transplants from related donors did your centre perform last year, and what were the one-year overall survival and non-relapse mortality rates?
- Which conditioning regimen will you use for my disease and fitness level, and why?
- What GvHD prophylaxis protocol do you follow, and what is your centre's rate of severe acute and chronic GvHD?
- What is included in the quoted price, and how is an extended stay or intensive-care admission priced?
- What are the discharge criteria, and what follow-up do I need in my home country?
- Who is the contact physician I call if I have symptoms after I return home?
Hospitals with Oncology in Turkey
Frequently asked questions
It is a procedure in which healthy stem cells from a compatible family member — usually a sibling — are infused into a patient after high-dose chemotherapy has destroyed the diseased marrow. The donor cells engraft and begin producing new, healthy blood cells over two to four weeks.
It is used mainly for blood cancers such as acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndrome, and for non-cancerous conditions including severe aplastic anaemia and certain inherited blood disorders. The transplant team confirms whether it is appropriate for your specific diagnosis and disease stage.
Approximate ranges run from €40,000 to €90,000 in Turkey, compared with roughly €120,000–€200,000 in the UK and €200,000–€400,000 in the United States. The final price depends on conditioning intensity, length of stay and what is included in the package; each centre provides a written quote.
Outcomes vary by disease, stage and patient age. For acute myeloid leukaemia in first complete remission, five-year survival after a matched sibling transplant is roughly 50–70 % in registry studies. For severe aplastic anaemia in younger patients it often exceeds 80 %. These are population averages; your team can discuss what the data show for your specific situation.
Graft-versus-host disease (GvHD) occurs when the donor immune cells attack the patient's tissues. Acute GvHD typically affects the skin, gut or liver in the first three months; chronic GvHD can affect many organs later. Moderate to severe chronic GvHD affects roughly 20–50 % of matched related donor recipients, depending on age and conditioning type. It is treated with immunosuppressive drugs.
The in-patient phase lasts four to eight weeks for an uncomplicated course. After discharge, intensive outpatient monitoring continues for at least three months. Most patients cannot work for three to six months. The immune system takes one to two years to fully recover, and repeat vaccinations are needed from about six months post-transplant.
The infusion itself causes minimal discomfort. The conditioning chemotherapy that precedes it typically causes nausea, mouth soreness, fatigue and hair loss, which is the most difficult phase. Supportive care — anti-emetics, mouth-care protocols and nutrition support — is part of the standard protocol.
The in-patient stay alone is typically four to eight weeks; you should allow at least two to three additional weeks of outpatient follow-up before travelling home. Plan for a family member or companion to accompany you throughout. Critical follow-up — GvHD monitoring, drug adjustment, infection management — must be continued by a haematologist in your home country.
An autologous transplant uses the patient's own previously collected stem cells; it carries no GvHD risk but no graft-versus-tumour effect either. An allogeneic transplant uses a donor's cells; this introduces GvHD risk but also gives a potentially therapeutic immune response against residual disease. The choice depends on the diagnosis.
JACIE accreditation (Joint Accreditation Committee of ISCT and EBMT) is the European standard for transplant programme quality. Ask the centre to confirm its status and to show how its outcomes compare with EBMT registry benchmarks. Accredited programmes are audited against defined standards for clinical practice, donor care and quality management.
Patient stories